Achieving a resolution like no other
We are continually pushing the boundaries of science and technology to enable early, actionable, and personalized diagnoses in our mission to improve and save lives. Our cutting-edge technologies are powering the discovery of new biology and accurate biomarkers that address scientific knowledge gaps and clinical unmet needs.
MiRXES was founded to commercialise our industry-leading ID3EAL reverse transcription quantitative polymerase chain reaction (RT-qPCR) platform for detection of microRNAs and other non-coding RNAs. This technology powers our flagship GASTROClear gastric cancer early detection test and is the foundation on which our multi-cancer early detection clinical pipeline is built.
Our technology is available for research use through our comprehensive range of Biopharma and Life Science discovery tools and services. We also collaborate extensively with clinical, academic, and industry partners on diagnostic applications in various disease areas, including cancer, cardiovascular diseases, metabolic diseases, and infectious diseases.
We are also developing and adopting new technologies for RNA-centric multi-omics diagnostics, harnessing the power of microRNA to complement other biomarkers for a more complete snapshot of disease biology and to enable early disease interception.
Unique RT Primer
Specific Real-Time PCR Primer
Tailored RT-qPCR Reagents
Optimized RT-qPCR primers and reagents ensure efficient target amplification from limited amounts (~1 pg) of input RNA
Every assay utilizes three microRNA-specific primers to discriminate between microRNAs with single nucleotide differences
RNA to CT results obtained in less than two hours
Assays are optimized by our proprietary algorithm and experimentally validated
Provided in a complete kit that minimises set-up time which is compatible with all major qPCR instruments
Our Innovation Engine
MicroRNAs are notoriously difficult to quantify accurately due to their high degree of homology and small size. Their low abundance in circulation aggravates this difficulty.
Our ID3EAL discovery tool and workflow is our solution. It is a unique three primer approach for sensitivity, specificity and robustness, adopted by top academic and industry partners globally and backed by the world’s first industry-standard for microRNA-based diagnostics.